As the mesenchymal transition of glioma cells correlates with a more invasive and treatment-resistant phenotype, indicating poor prognosis and recurrence in patients with GBM, down-regulated CACNG3 in the mesenchymal molecular subtype suggests a poor prognosis. This evidence concerns the gene CACNG3 and glioma.